Objective. YKL-40, also called human cartilage glycoprotein-39, is secreted by chondrocytes, synovial cells, macrophages and neutrophils. Studies have shown that YKL-40 is an autoantigen in rheumatoid arthritis (RA). We evaluated whether serum YKL-40 was related to disease activity in patients with RA.
The aetiology of rheumatoid arthritis (RA) is unknown.
Verheijden et al. [11] have recently reported that HC gp-39 contains several DR4 peptide binding motifs and However, autoimmune mechanisms play a central role that it may be a target of the immune response in RA. in the pathogenesis of the disease [1] . A prevailing view When HC gp-39 was injected into BALB/c mice, a is that the chronic inflammation in patients with RA is chronic relapsing arthritis was found and inhalation of mediated by antigen-induced activation of T cells infilthe protein led to tolerization of antigen-specific T cells trating the synovial membrane, which then induces and in suppression of the HC gp-39 induced arthritis. inflammatory processes resulting in synovial prolifer-
The physiological function of YKL-40 is unknown. ation associated with resorption of cartilage and bone YKL-40 is a chitin-binding lectin [12] , but has no [2] [3] [4] .
chitinase activity. The pattern of its expression in normal YKL-40 (the protein has been termed YKL-40 from and disease states suggests that YKL-40 may play a role its molecular weight (40 kDa) and the one-letter code in remodelling or degradation of the extracellular matrix for its three N-terminal amino acids [16 ] ), also named and in the inflammatory process [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . YKL-40 human cartilage glycoprotein-39 [5], is a mRNA expression is found in human articular cartilage mammalian member of the family of 18 glycosyl and synovium from patients with RA, but cannot be hydrolases which includes bacterial chitinases [5] [6] [7] [8] [9] [10] .
detected in articular cartilage from normal subjects [5, 7] . In primary cultures of articular cartilage chondro- Submitted 17 July 1998; revised version accepted 25 February 1999. cytes and synovial cells from patients with RA or proteins found in conditioned culture medium [5, 7, 13] .
In situ hybridization studies of inflamed synovial tissue classification criteria [24] . None of the patients had any known cancer, liver or lung disease at entry or had from patients with RA have demonstrated that YKL-40 is expressed in macrophages in vivo [14] . YKL-40 is developed these diseases by August 1997 (5 yr after inclusion in the study). A total of 137 patients were expressed in vitro by activated macrophages [8, 12, 14] and is exocytosed by activation from the specific grantreated with DMARD during the 1 yr study period: methotrexate (MTX ) (n = 49), sulphasalazine (n = 43), ules of neutrophils [15] .
In a previous study, we have reported increased serum penicillamine (n = 21), ercoquin (n = 8), gold (n = 10), imurel (n = 5), cyclosporin (n = 1) or no DMARD concentrations of YKL-40 in patients with RA, a 10-fold increase in the synovial fluid concentration compared to (n = 19). None of the patients received DMARD combination therapy. Twenty-five patients received predniserum YKL-40, and a positive correlation between the serum and synovial fluid concentrations of . solone p.o. initially. The patients continued with this DMARD therapy throughout the study period, but the Consequently, YKL-40 may be directly involved in the process of inflammation and tissue degradation in dosages were allowed to be modified accordingly to disease activity. the arthritic joint. If so, measurement of YKL-40 in serum may provide new information on the arthritic
The patients were followed with clinical and biochemical controls at day 30, 60, 90, 120, 150, 180, 270 and disease activity compared to the more indirect measures using conventional biochemical markers, serum 360. Patients in study II also had controls at day 1, 7 and 14. Data collected at each visit included the number C-reactive protein (CRP) and the erythrocyte sedimentation rate ( ESR). [21, 22] . Study I was primarily perjoint (× 8), remaining metatarsophalangeal joints (× 5). The patients were divided into three groups at baseline formed to determine the bone mineral density in patients with RA and to evaluate parameters of importance for according to disease activity [21] . Group I: 105 patients with clinically active and biochemically active disease monitoring inflammatory activity in relation to bone loss in these patients [21] . Study II was performed to defined by the presence of >2 groups of swollen joints and at least two of the following criteria: morning evaluate whether prednisolone therapy in combination with disease-modifying anti-rheumatic drug (DMARD) stiffness lasting >60 min, ESR > 35 mm in the first hour (normal range: <20 mm/h and serum CRP Á is superior to DMARD therapy alone in a randomized longitudinal study. Patients with clinically active RA, 150 nmol/l (normal range: <90 nmol/l ). Group II: 31 patients with clinically active disease but biochemically planned either to start or change DMARD therapy, were randomly allocated to treatment with DMARD inactive disease defined by the presence of >2 groups of swollen joints, morning stiffness lasting >60 min, only (n = 38) or in combination with prednisolone (n = 43). Prednisolone therapy was given as 30 mg pred-ESR ∏30 mm/h and serum CRP < 150 nmol/l. Group III: 20 patients with clinically inactive and biochemically nisolone perorally (p.o.) daily the first week, 20 mg prednisolone p.o. daily the second week and 15 mg p.o.
inactive disease defined by ∏2 swollen joints, morning stiffness lasting <30 min, ESR ∏30 mm/h and serum at day 15. The patients were then instructed to choose a prednisolone dose between 2.5 and 15 mg sufficient to CRP < 150 nmol/l. control their disease activity [22] . The studies were Biochemical analysis approved by the local ethical committees of the participating centres. In accordance with the Helsinki Blood samples were collected between 8 a.m. and 2 p.m., allowed to clot at room temperature and then centriDeclaration II, each patient was informed about the study verbally and in writing, and all gave their written fuged at 2000 g for 10 min. The serum and plasma samples were either analysed immediately or stored at consent. The patients were informed of the possibility of withdrawing from the study at any time.
−80°C until all samples from the 1 yr study were collected (for serum YKL-40 and PIIINP analysis). The study included 156 patients (75 patients from study I and 81 from study II; 125 women and 31 men, Serum CRP was analysed with nephelometry. ESR, haemoglobin, leucocytes, serum alkaline phosphatase, aged 20-83 yr) with RA according to the American College of Rheumatology criteria for this disease [23] .
serum aspartate aminotransferase, serum albumin and serum creatinine were determined by routine methods. Eighty patients were in functional class I, 72 in class II and four in class III according to the Steinbrocker PIIINP in serum was determined by radioimmunoassay limit = 208 mg/l ) [20] . There was no difference between genders (P = 0.65, Wilcoxon two-sample test), but a weak correlation with age (Spearman 0.30).
X-ray
Radiographs of the hands and wrist at entry and 1 yr later were evaluated blindly by the same experienced radiologist in randomly ordered groups. Each finger and wrist joint was scored according to the method of Larsen et al. [27] , which grades joint damage on a scale from 0 (a radiologically normal joint) to 5 (a joint with maximal destruction) with reference to a standard atlas of radiographs. Progression was considered to be any magnitude of increase in Larsen score. calculated by the Spearman rho test and P values of <0.05 were considered significant. The course of the changes in serum YKL-40, serum CRP and ESR were (RIA) (PIIINP RIA kit, Orion Diagnostica, Finland) [26 ] . Serum YKL-40 was determined by RIA [6 ] using expressed in time-integrated values, and the area under the curve (AUC ) was calculated for each patient during rabbit antibody raised against human YKL-40. Purified human YKL-40 was used for standard and tracer. The the study using 9-12 time points (i.e. day 0, 1, 7, 14, 30, 60, 90, 120, 150, 180, 270 and 360) [28]. Pearson's tracer was prepared by the iodogen (Pierce and Warriner, Chester Ltd, UK ) method and antibodytest was used to evaluate whether a relationship existed between progression in Larsen score and a persistently bound and free 125I-labelled YKL-40 were separated by use of Sac-Cel (a donkey anti-rabbit antibody-coated elevated serum YKL-40, serum CRP and ESR (e.g. YKL-40 AUC >208 mg/l, CRP AUC >150 nmol/l and cellulose suspension; Wellcome Diagnostics Ltd, UK ). The intra-assay and interassay variations were <6.5%
Statistical analysis
ESR AUC > 30 mm/h). To estimate the longitudinal changes in serum YKL-40 during treatment, the initial and <12%, and the sensitivity was 20 mg/l. To eliminate the interassay variation, samples from each patient were values of serum YKL-40, serum CRP and ESR were set at 100%, and values obtained after institution of treatanalysed in the same assay. The median serum YKL-40 in 260 healthy adults, 116 males and 144 females, with ment were expressed as a percentage of the initial value. Differences between the percentage changes in serum a median age of 48 yr (range 18-79 yr) was 102 mg/l (range 38-514 mg/l, upper 90th per cent confidence YKL-40, serum CRP and ESR between the two treat- Values are Spearman's rho. **P < 0.01; ***P < 0.001; -, non-significant.
PIIINP, the amino-terminal propeptide of human type III procollagen.
aAn area-weighted swollen joint index was calculated according to Lansbury and Haut [25] , where each swollen joint is multiplied by a factor weighted for the relative joint surface area (see Materials and methods). 
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ment groups (study II; ± prednisolone) were estimated YKL-40 or between normal acute-phase proteins and normal serum YKL-40 in the patients with clinically by Student's t-test for unpaired data.
active disease (Groups I and II ). Seventy-four (54%) of these 136 patients had elevated serum YKL-40 levels, Results 92 (68%) had elevated serum CRP and 83 (61%) had increased ESR. In 51 of these 136 patients, all three Serum YKL-40 in relation to disease activity biochemical parameters were elevated, 23 patients had Baseline clinical and demographic features of the normal levels of all three parameters, 10 patients had patients according to disease activity are presented in normal acute-phase proteins but elevated serum Table 1 . The groups were similar in age, disease duration YKL-40, 29 patients had elevated acute-phase proteins and sex ratio. Patients with clinically and biochemically but normal YKL-40, 10 patients had elevated serum active RA (Group I ) had higher serum YKL-40 (median YKL-40 and either increased serum CRP or ESR, seven 234 mg/l, range 43-1088 mg/l ) than patients with clinichad only an elevation in ESR and six had only an ally active but biochemically inactive disease (164 mg/l, elevation in serum CRP. Serum YKL-40 correlated range 58-736 mg/l; P = 0.0046) (Group II ), patients initially (all patients) with ESR (Spearman's rho 0.42) with clinically and biochemically inactive disease and serum CRP (rho 0.38), but the correlation coeffi-(170 mg/l, range 136-526 mg/l; P = 0.0603) (Group III ) cients were much lower than that between ESR and and age-matched controls (102 mg/l; P < 0.01). The CRP (rho 0.73) ( Table 2 ). In study II, serum YKL-40 individual serum YKL-40 concentrations according to correlated with ESR and serum PIIINP throughout the disease activity are illustrated in Fig. 1 . Sixty per cent study period ( ESR not at day 60), and with serum CRP of the patients in Group I had increased levels of serum after day 60. During the first 6 months, serum YKL-40 YKL-40 (e.g. >208 mg/l; 90th percentile of controls) correlated with the area-weighted swollen joint index, and serum YKL-40 decreased significantly (−30%, but was not related to the total number of large or small P < 0.002) in the patients who became clinically and swollen joints, total number of large or small tender biochemically inactive at 12 months (n = 22). Patients joints, HAQ score, grip strength, or doctor's and who remained active during the study period had patient's visual analogue scale. unchanged serum YKL-40. Ten patients changed from Serum YKL-40 in relation to progression in Larsen inactive to active disease and they had an increase in score serum YKL-40 of 50% (P < 0.05).
There was not always a close relationship between The variations in the biochemical parameters were expressed in time-integrated values during the study and elevated acute-phase proteins and elevated serum the AUC was calculated [28] . Forty-one patients were phase response, serum CRP and ESR, are considered to be suitable biochemical markers for long-term monibiochemically inactive throughout the 1 yr study period (i.e. normal serum CRP and ESR), and 15 of these toring of disease activity in RA [29] [30] [31] . Radiological progression, including loss of joint space, bone erosions patients had a progression in Larsen score (median progression score = 2, range 1-5). Persistently elevated or subchondral cysts, represents one of the outcome measures in RA and the progression in the small hand serum YKL-40 ( YKL-40 AUC > 208 mg/l ) was found in nine of these biochemically inactive patients with joints parallels the radiological changes in other joints [32] . However, differences exist between clinical disease clinically active disease and a progression in Larsen score.
activity and the level of ESR or serum CRP. Normal values of ESR and CRP are found in patients with Twenty-seven of the 50 patients with early RA (disease duration <3 yr, 16 from study I and 34 from study II ) apparently clinically active disease [29, 31] , and the development of bone erosions in the hands from patients had a progression in Larsen score after 1 yr (median progression score = 3, range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . The initial concenwith early RA can occur independently of clinical symptoms and the acute-phase response [33] . Additional trations of serum YKL-40, serum CRP and ESR were not related to the progression in Larsen score. By biochemical markers of disease activity are therefore needed. contrast, a persistently elevated serum YKL-40 ( YKL-40 AUC >208 mg/l ) was related to a progression Our present findings confirm that serum YKL-40 is influenced by the disease activity in RA as evaluated by in Larsen score (Pearson's test, P = 0.0075). Persistently increased ESR ( ESR AUC >30 mm/h) was also related clinical markers of disease activity as well as by ESR and CRP. Serum YKL-40 was increased in 54% of the to progression in Larsen score (P = 0.041), whereas a persistently elevated serum CRP (CRP AUC > patients with clinically active RA. Patients with clinically active disease who became inactive during the study had 50 nmol/l ) was not related to a progression in Larsen score (P = 0.70). a significant decrease in serum YKL-40, whereas patients who remained clinically active had unchanged serum Changes in serum YKL-40 during treatment with YKL-40 levels. Patients changing from clinically inactive DMARD only or in combination with prednisolone to active disease showed an increase in serum YKL-40.
(study II)
Furthermore, serum YKL-40 had a predictive value for the risk of radiological progression of joint damage in In patients treated with prednisolone in combination with MTX (n = 18), serum YKL-40 was 15% below patients with early RA. In some patients, serum YKL-40 provided informainitial levels after only 1 day (P < 0.01) and was 33% below initial levels after 30 days (P < 0.001). In patients tion on disease activity different from that of ESR and serum CRP. An elevated serum concentration of treated with MTX only (n = 17), serum YKL-40 was reduced by 15% after 60 days (P < 0.01). The percentage YKL-40 was observed in some patients showing radiological progression in Larsen score, but with normal change in serum YKL-40 between the two treatment groups was statistically significant during the first month levels of the acute-phase reactants, and normal serum YKL-40 levels were observed in some patients with (P < 0.05-P < 0.001) (Fig. 2) . Patients treated with other DMARDs without prednisolone had a slower biochemically and clinically active disease. The decrease in serum YKL-40 in patients treated with DMARD in decrease in serum YKL-40, being statistically significant after 6 months (−13%, P < 0.05). Most of the patients combination with prednisolone was much lower compared to that observed in the acute-phase proteins. Low, in the prednisolone-treated group either stopped prednisolone therapy or continued with a low dose at albeit significant, correlations were found between serum YKL-40 and ESR and serum CRP, but less significant 6 months. At this time, no difference in serum YKL-40 was found between the two treatment groups. Serum than the correlation between ESR and serum CRP. YKL-40 also correlated with the area-corrected swollen CRP was decreased by 74% and ESR by 71% (P < 0.001) after 14 days, and the levels in the prednisojoint score and serum PIIINP, a biochemical marker of the formation of type III collagen as part of synovial lone-treated patients were significantly lower than those in patients treated with DMARD only until day 90 inflammation [34, 35] . Our results indicate that serum YKL-40 may reflect (serum CRP) or day 180 ( ESR) (P < 0.05-P < 0.001) (Fig. 2) . a different and more local aspect of the inflammatory process than serum CRP and ESR in patients with RA. At 1 yr, 12 patients were clinically and biochemically inactive and had a decrease in serum YKL-40 of 36%
The acute-phase proteins are not secreted by the cells in an arthritic joint, but their circulating levels represent a (P < 0.001) compared to the initial values. None of these patients had an elevated serum YKL-40 at 12 non-specific distant response by hepatocytes to mediators like interleukin-6, tumour necrosis factor and months.
interleukin-1b [36, 37] . YKL-40 is not secreted by hepatocytes [19] and a plausible explanation of the Discussion elevated serum YKL-40 levels in patients with active RA would be that the protein is secreted in excess in Chronic active inflammation of the rheumatoid joint often leads to irreversible destruction of articular cartilthe arthritic joint. This assumption is supported by the findings in our previous study [6 ] . We observed a 10-fold age and subchondral bone. Measurements of the acute-higher concentration of YKL-40 in synovial fluid comof the American College of Rheumatology, [8] [9] [10] [11] [12] November 1997 in Washington, USA, and at the 27th pared to serum in patients with RA, as well as a positive relationship between YKL-40 levels in serum and synScandinavian Congress of Rheumatology, 5-8 June 1998 in Aarhus, Denmark. This study was supported by ovial fluid. YKL-40 can originate from articular chondrocytes [5, 7] , synovial cells (probably activated grants from Dagmar Marshalls Fond, Michaelsen Fonden, Overlaege Johan Boserup og Lise Boserups macrophage or macrophage-like cells in the inflamed synovial membrane) [13, 14] or from exocytosis of legat and the Danish Rheumatism Association. YKL-40 in the specific granules of neutrophils [15] found in large amounts in the synovial fluid and in the
